7 completed, 1 active not recruiting, 1 unknown. 8 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 6, Active not recruiting 1, Unknown 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow RT001: new trials by email Literature Review of RT001 trials Research Report on RT001
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY RT001, Placebo - Progressive Supranuclear Palsy | Phase 2 | Unknown | Biojiva LLC | 40 | 2021-06-23 | 2021-06-25 |
| RT001 in Amyotrophic Lateral Sclerosis RT001, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 | Completed | Biojiva LLC | 43 | 2021-03-10 | 2025-07-01 |
| A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia RT001, Placebo - Friedreich's Ataxia | Phase 3 | Completed | Biojiva LLC | 65 | 2019-10-30 | 2022-05-27 |
| A Study to Assess Efficacy and Safety of RT001 in Subjects With Infantile Neuroaxonal Dystrophy RT001 - Infantile Neuroaxonal Dystrophy | Phase 2 / Phase 3 | Active not recruiting | Biojiva LLC | 19 | 2018-11-05 | 2021-10-14 |
| A First in Human Study of RT001 in Patients With Friedreich's Ataxia Low dose cohort, High dose cohort - Friedreich's Ataxia | Phase 1 / Phase 2 | Completed | Biojiva LLC | 19 | 2015-08-01 | 2020-11-27 |
| Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults RT001 - Lateral Canthal Lines, Crow's Feet | Phase 2 | Completed | Revance Therapeutics, Inc. | 40 | 2010-05-01 | 2014-01-17 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines RT001, Placebo - Lateral Canthal Lines | Phase 2 | Completed | Revance Therapeutics, Inc. | 72 | 2009-04-01 | 2014-01-17 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines Vehicle Control, RT001 (Botulinum Toxin Type A Topical Gel) - Lateral Canthal Lines | Phase 2 | Completed | Revance Therapeutics, Inc. | 30 | 2009-02-01 | 2020-08-28 |
| Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines RT001, Vehicle Comparator - Lateral Canthal Lines, Crow's Feet | Phase 2 | Completed | Revance Therapeutics, Inc. | 60 | 2008-11-01 | 2013-11-19 |
Friedreich Ataxia (2) · Amyotrophic Lateral Sclerosis (1) · Neuroaxonal Dystrophies (1) · Supranuclear Palsy, Progressive (1)
Biojiva LLC (5) · Revance Therapeutics, Inc. (4)
United States (7) · Estonia (1) · Germany (1) · Latvia (1) · Netherlands (1) · Sweden (1)
Peter Milner, MD (2) · Curtis Scribner, MD (1) · Debbie Tranowski (1) · Joel Schlessinger, M.D. (1) · Leonard van den Berg, MD (1) · Stefan Lorenzl, MD, PhD (1) · Suzanne Bruce, MD (1) · Theresa Zesiewicz, MD (1)